

FINAL RESUME ON THE RESEARCH UNIT:
Anti-tumoral immunology and immunotherapy
of cancers (ITIC)

UNDER THE SUPERVISION OF THE
FOLLOWING INSTITUTIONS AND
RESEARCH BODIES:

Université Paris-Sud

Institut National de la Santé et de la Recherche
Médicale - INSERM

Centre de Lutte Contre le Cancer de Villejuif -
Institut Gustave Roussy

EVALUATION CAMPAIGN 2018-2019
GROUP E



In the name of Hcéres¹:

Michel Cosnard, President

In the name of the experts committee²:

Andreas Mackensen, Chairman of the
committee

Under the decree No.2014-1365 dated 14 November 2014,

¹ The president of Hcéres "countersigns the evaluation reports set up by the experts committees and signed by their chairman." (Article 8, paragraph 5);

² The evaluation reports "are signed by the chairman of the experts committee". (Article 11, paragraph 2).

Tables in this document were filled with data provided by laboratories and supervising bodies in the unit's application and in the Excel files "Données du contrat en cours" and "Données du prochain contrat".

UNIT PRESENTATION

Unit name:	Anti-tumoral immunology and immunotherapy of cancers
Unit acronym:	ITIC
Requested label:	UMR
Application type:	Restructuration
Current number:	1015
Head of the unit (2018-2019):	Ms Laurence ZITVOGEL
Project leader (2020-2024):	Ms Laurence ZITVOGEL
Number of teams and/or themes:	3

EXPERTS COMMITTEE MEMBERS

Chair:	Mr Andreas MACKENSEN, University of Erlangen, Germany
Experts:	Ms Evelina GATTI, Centre d'Immunologie Marseille-Luminy Ms Virginie LAFONT, Institut de Recherche en Cancérologie de Montpellier (representative of Inserm CSS) Mr Daniel OLIVE, Institut de Cancérologie et d'Immunologie de Marseille (representative of CNU) Mr Nicolas SETTERBLAD, Institut Universitaire d'Hématologie, Paris (supporting personnel)

HCÉRES REPRESENTATIVE

Ms Sophie EZINE

REPRESENTATIVES OF SUPERVISING INSTITUTIONS AND BODIES

Mr Étienne AUGE, Université Paris Sud
Mr David BOUCARD, Institut Gustave Roussy
Ms Guia CARRARA, Inserm
Mr Marc HUMBERT, Université Paris Sud
Ms Laurence PARMANTIER, Inserm

INTRODUCTION

HISTORY AND GEOGRAPHICAL LOCATION OF THE UNIT

The Research Unit UMR_S1015 « Immunology of Tumors and Cancer Immunotherapy, ITIC » is hosted since 2003 in the Institut Gustave Roussy Cancer Center (GRCC), in Villejuif, in the southern Paris area. The laboratory is located on the 12th floor of the Hospital building.

The Research Unit is supported by Inserm (Institut National de la Santé et de la Recherche Médicale), GRCC and University Paris-Saclay.

MANAGEMENT TEAM

Ms Laurence ZITVOGEL heads the research unit.

HCÉRES NOMENCLATURE

SVE3_4 Immunologie

SCIENTIFIC DOMAIN

At the beginning of the last contract (2014-2018), the unit was focusing on: 1) the relationship between immunogenic cell death and gut microbiota in the context of immune checkpoint blockade; and 2) the development of new cancer vaccines based on pioneer translation products (PTPs). For the next mandate, a focus on translational research on a “bench to bedside” approach and the development of a platform for preclinical testing of novel compounds was established.

UNIT WORKFORCE

	Unit workforce	
	Unit ITIC	
Active staff	Number 30/06/2018	Number 01/01/2020
Full professors and similar positions	1	1
Assistant professors and similar positions	0	0
Full time research directors (Directeurs de recherche) and similar positions	0	0
Full time research associates (Chargés de recherche) and similar positions	1	1
Other scientists (“Conservateurs, cadres scientifiques des EPIC, fondations, industries, etc.”)	0	0
High school teachers	0	0
Supporting personnel (ITAs, BIATSSs and others, notably of EPICs)	17	17

Permanent staff	19	19
Non-permanent professors and associate professors, including emeritus	4	
Non-permanent full time scientists, including emeritus, post-docs	8	
<i>PhD Students</i>	7	
Non-permanent supporting personnel	3	
Non-permanent staff	22	
Total	41	19

GLOBAL ASSESSMENT OF THE UNIT

The “Immunology of Tumors and Cancer Immunotherapy” unit U1015 demonstrates a sustained capacity to be at the forefront of translational tumour immunology and immunotherapy of cancer and to be worldwide-internationally recognized in this field. One major finding is the characterization of immunogenic cell death, paving the way to the success of immune checkpoint blockade and adoptive T cell transfer.

Furthermore, the unit was the first to describe the impact of the gut microbiome on tumour immunology and antitumor responses. Remarkable interactions with the clinics and medical collaborations as well as networking together with the support of a number of organisations such as H2020, EU grants, RHU, has enhanced the research excellence from bench to bedside and back. The unit has developed a very strong ability to train PhDs and post-docs with an excellent rate of success and efforts are devoted to increase the number of “habilitation à diriger la recherche” (HDR).

The evaluation reports of Hceres
are available online : www.hceres.com

Evaluation of clusters of higher education and research institutions
Evaluation of higher education and research institutions
Evaluation of research
Evaluation of doctoral schools
Evaluation of programmes
International evaluation and accreditation



2 rue Albert Einstein
75013 Paris, France
T. 33 (0)1 55 55 60 10

hceres.com

[@Hceres_](https://twitter.com/Hceres_)

[Hcéres](https://www.youtube.com/Hceres)